These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20647856)

  • 21. Torcetrapib: when global risk reduction goes 'off target'.
    Jackson G
    Int J Clin Pract; 2008 Feb; 62(2):173-4. PubMed ID: 18199271
    [No Abstract]   [Full Text] [Related]  

  • 22. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 23. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.
    Lavie CJ; Milani RV
    J Am Coll Cardiol; 2008 Jan; 51(1):56-8. PubMed ID: 18174037
    [No Abstract]   [Full Text] [Related]  

  • 25. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 26. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit.
    Taylor J
    Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754
    [No Abstract]   [Full Text] [Related]  

  • 27. The off-target effects of torcetrapib.
    Funder JW
    Endocrinology; 2009 May; 150(5):2024-6. PubMed ID: 19383878
    [No Abstract]   [Full Text] [Related]  

  • 28. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
    Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The failure of torcetrapib: was it the molecule or the mechanism?
    Tall AR; Yvan-Charvet L; Wang N
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
    [No Abstract]   [Full Text] [Related]  

  • 30. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
    Olsson AG; Nilsson PM
    Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
    [No Abstract]   [Full Text] [Related]  

  • 31. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

  • 32. Raising high-density lipoprotein: for better or worse?
    Tomlinson B
    Heart; 2010 Sep; 96(17):1339-40. PubMed ID: 20801851
    [No Abstract]   [Full Text] [Related]  

  • 33. High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.
    Levy Y
    Cardiovasc Res; 2008 Mar; 77(4):614-5. PubMed ID: 18187459
    [No Abstract]   [Full Text] [Related]  

  • 34. Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity?
    Sloop GD; Weidman JJ; St Cyr JA
    Ther Adv Cardiovasc Dis; 2015 Apr; 9(2):32-5. PubMed ID: 25573766
    [No Abstract]   [Full Text] [Related]  

  • 35. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

  • 36. HDL-cholesterol levels and cardiovascular risk: acCETPing the context.
    Lange RA; Lindsey ML
    Eur Heart J; 2008 Nov; 29(22):2708-9. PubMed ID: 18957471
    [No Abstract]   [Full Text] [Related]  

  • 37. Cholesteryl ester transfer protein inhibition: a dysfunctional endothelium.
    Westerterp M; Koetsveld J; Tall AR
    J Cardiovasc Pharmacol; 2010 May; 55(5):456-8. PubMed ID: 20351566
    [No Abstract]   [Full Text] [Related]  

  • 38. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.
    Hermann F; Enseleit F; Spieker LE; Périat D; Sudano I; Hermann M; Corti R; Noll G; Ruschitzka F; Lüscher TF
    Thromb Res; 2009; 123(3):460-5. PubMed ID: 18789492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of dalcetrapib.
    Stein EA; Stroes ES; Steiner G; Buckley BM; Capponi AM; Burgess T; Niesor EJ; Kallend D; Kastelein JJ
    Am J Cardiol; 2009 Jul; 104(1):82-91. PubMed ID: 19576325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.